vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and XPLR Infrastructure, LP (XIFR). Click either name above to swap in a different company.
XPLR Infrastructure, LP is the larger business by last-quarter revenue ($249.0M vs $177.4M, roughly 1.4× Pacira BioSciences, Inc.). XPLR Infrastructure, LP runs the higher net margin — 11.2% vs 1.6%, a 9.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -15.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -1.6%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
XPLR Infrastructure is a publicly traded subsidiary of NextEra Energy, is a Juno Beach, Florida-based renewable energy company.
PCRX vs XIFR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $249.0M |
| Net Profit | $2.9M | $28.0M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | -19.3% |
| Net Margin | 1.6% | 11.2% |
| Revenue YoY | 5.0% | -15.3% |
| Net Profit YoY | — | 124.3% |
| EPS (diluted) | $0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $249.0M | ||
| Q3 25 | $179.5M | $315.0M | ||
| Q2 25 | $181.1M | $342.0M | ||
| Q1 25 | $168.9M | $282.0M | ||
| Q4 24 | $187.3M | $294.0M | ||
| Q3 24 | $168.6M | $319.0M | ||
| Q2 24 | $178.0M | $360.0M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $28.0M | ||
| Q3 25 | $5.4M | $-37.0M | ||
| Q2 25 | $-4.8M | $79.0M | ||
| Q1 25 | $4.8M | $-98.0M | ||
| Q4 24 | — | $-115.0M | ||
| Q3 24 | $-143.5M | $-40.0M | ||
| Q2 24 | $18.9M | $62.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -19.3% | ||
| Q3 25 | 3.5% | 1.6% | ||
| Q2 25 | 4.7% | 26.3% | ||
| Q1 25 | 1.2% | -82.6% | ||
| Q4 24 | 13.2% | -188.1% | ||
| Q3 24 | -82.8% | 15.4% | ||
| Q2 24 | 15.9% | 18.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 11.2% | ||
| Q3 25 | 3.0% | -11.7% | ||
| Q2 25 | -2.7% | 23.1% | ||
| Q1 25 | 2.8% | -34.8% | ||
| Q4 24 | — | -39.1% | ||
| Q3 24 | -85.1% | -12.5% | ||
| Q2 24 | 10.6% | 17.2% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | $-0.40 | ||
| Q2 25 | $-0.11 | $0.84 | ||
| Q1 25 | $0.10 | $-1.05 | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | $-0.43 | ||
| Q2 24 | $0.39 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $960.0M |
| Total DebtLower is stronger | — | $6.2B |
| Stockholders' EquityBook value | $653.9M | $10.9B |
| Total Assets | $1.2B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.57× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $960.0M | ||
| Q3 25 | $246.3M | $711.0M | ||
| Q2 25 | $445.9M | $880.0M | ||
| Q1 25 | $493.6M | $1.5B | ||
| Q4 24 | $484.6M | $283.0M | ||
| Q3 24 | $453.8M | $290.0M | ||
| Q2 24 | $404.2M | $281.0M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $6.2B | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $5.3B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $10.9B | ||
| Q3 25 | $727.2M | $11.0B | ||
| Q2 25 | $757.8M | $11.3B | ||
| Q1 25 | $798.5M | $12.6B | ||
| Q4 24 | $778.3M | $12.9B | ||
| Q3 24 | $749.6M | $13.6B | ||
| Q2 24 | $879.3M | $13.9B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $19.6B | ||
| Q3 25 | $1.3B | $19.1B | ||
| Q2 25 | $1.5B | $20.5B | ||
| Q1 25 | $1.6B | $21.4B | ||
| Q4 24 | $1.6B | $20.3B | ||
| Q3 24 | $1.5B | $20.9B | ||
| Q2 24 | $1.6B | $21.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.57× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.41× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $186.0M |
| Free Cash FlowOCF − Capex | — | $-88.0M |
| FCF MarginFCF / Revenue | — | -35.3% |
| Capex IntensityCapex / Revenue | — | 110.0% |
| Cash ConversionOCF / Net Profit | — | 6.64× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-219.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $186.0M | ||
| Q3 25 | $60.8M | $231.0M | ||
| Q2 25 | $12.0M | $232.0M | ||
| Q1 25 | $35.5M | $90.0M | ||
| Q4 24 | $33.1M | $283.0M | ||
| Q3 24 | $53.9M | $208.0M | ||
| Q2 24 | $53.2M | $231.0M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-88.0M | ||
| Q3 25 | $57.0M | $-283.0M | ||
| Q2 25 | $9.3M | $151.0M | ||
| Q1 25 | $26.9M | $1.0M | ||
| Q4 24 | $31.0M | $231.0M | ||
| Q3 24 | $49.8M | $152.0M | ||
| Q2 24 | $51.6M | $162.0M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -35.3% | ||
| Q3 25 | 31.7% | -89.8% | ||
| Q2 25 | 5.1% | 44.2% | ||
| Q1 25 | 15.9% | 0.4% | ||
| Q4 24 | 16.6% | 78.6% | ||
| Q3 24 | 29.6% | 47.6% | ||
| Q2 24 | 29.0% | 45.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 110.0% | ||
| Q3 25 | 2.2% | 163.2% | ||
| Q2 25 | 1.5% | 23.7% | ||
| Q1 25 | 5.1% | 31.6% | ||
| Q4 24 | 1.1% | 17.7% | ||
| Q3 24 | 2.4% | 17.6% | ||
| Q2 24 | 0.9% | 19.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.64× | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | 2.94× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | 3.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
XIFR
| Renewable Energy Sales | $238.0M | 96% |
| Related Party | $8.0M | 3% |
